Skip to main
ALPN
ALPN logo

ALPN Stock Forecast & Price Target

ALPN Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 27%
Hold 36%
Sell 0%
Strong Sell 0%

Bulls say

Alpine Immune Sciences is showing promising results in their clinical trials of povetacicept for treating autoimmune diseases, with superior outcomes compared to current treatments and a strong potential for use in multiple indications. The recent positive data presented at a key nephrology conference and the significant increase in stock price reflect a growing confidence in the company's potential. With other ongoing studies in different indications, there is potential for even more growth and development for Alpine Immune Sciences.

Bears say

Alpine Immune Sciences is facing significant downside risks as its main pipeline candidates, ALPN-303/ALPN-101, may not prove to be efficacious and could face commercial challenges from current and future therapies. In addition, there is limited visibility on the progress and data of the acazicolcept program, leading to a modest outlook on its potential. The current treatment options for autoimmune and inflammatory diseases also have their own limitations, highlighting the potential risks and uncertainties surrounding Alpine's pipeline candidates.

ALPN has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 27% recommend Buy, 36% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alpine Immune Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alpine Immune Sciences (ALPN) Forecast

Analysts have given ALPN a Buy based on their latest research and market trends.

According to 11 analysts, ALPN has a Buy consensus rating as of Aug 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alpine Immune Sciences (ALPN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.